Table 3.
Cancer nanotheranostics in clinical trials.
| Drug Name | Composition | Imaging Label (Modality) | Therapeutic Agent (Mechanism) | NCT | Phase(s) | Cancer Type |
|---|---|---|---|---|---|---|
| [64Cu]MM-302 | HER2-targeted 64Cu-labeled liposome containing doxorubicin | 64Cu (PET) | Doxorubicin (chemotherapy) | NCT01304797 | I | Breast cancer |
| NCT02213744 | II | |||||
| [89Zr]-Df-CriPec® | 89Zr labeled micellar docetaxel conjugate | 89Zr (PET) | Docetaxel (chemotherapy) | NCT03712423 | I | Solid Tumor |
| AGuIX® | Polysiloxane matrix nanoparticles with Gd chelates | Gd (MRI) | Gd (radiosensitizer) | NCT02820454 | I | Multiple brain metastases |
| NCT03818386 | II | |||||
| NCT04899908 | II | |||||
| NCT03308604 | I | Locally advanced cervical cancer | ||||
| NCT04881032 | I/II | Newly Diagnosed Glioblastoma | ||||
| NBTXR3 | Hafnium oxide nanoparticles | Hafnium oxide (CT) | Hafnium oxide (radioenhancer) | NCT01433068 | I | Soft tissue sarcoma |
| NCT02379845 | II/III | |||||
| NCT02805894 | I/II | Prostate adenocarcinoma | ||||
| NCT04505267 | I | Non-small cell lung cancer | ||||
| NCT04834349 | II | Head and neck squamous cell cancer (inoperable or recurrent) | ||||
| NCT04484909 | I | Pancreatic cancer | ||||
| NCT04615013 | I | Esophageal adenocarcinoma | ||||
| NCT04862455 | II | Head and neck squamous cancer (recurrent or metastatic) | ||||
| NCT05039632 | II | |||||
| NCT04892173 | III | Locally advanced squamous cell carcinoma |